Disease‐modifying treatments for multiple sclerosis – a review of approved medications

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 23, Iss. S1, 2016-01 ,pp. : 18-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs*

By Birnbaum Howard G.   Ivanova Jasmina I.   Samuels Seth   Davis Matthew   Cremieux Pierre Y.   Phillips Amy L.   Meletiche Dennis  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 869-877

Informa Healthcare

Access to resources Recommend Favorite

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment

By Lage Maureen J.   Carroll Cathryn A.   Fairman Kathleen A.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1146-1153

Informa Healthcare

Access to resources Recommend Favorite

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite

Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

By Reynolds Matthew W.   Stephen Reejis   Seaman Chris   Rajagopalan Kitty  

Current Medical Research and Opinion, Vol. 26, Iss. 3, 2010-03 ,pp. : 663-674

Informa Healthcare

Access to resources Recommend Favorite